Pfizer's Berobenatide Shows Nearly 16% Weight Loss in Phase 2b, Monthly Dosing Possible
PFE is trading near its 52-week low of $23.08 (12% above the low).
Summary
Pfizer announced strong Phase 2b clinical trial results for its obesity drug candidate, Berobenatide (Vesper-1), demonstrating nearly 16% weight loss at 32 weeks with a 2.4 mg weekly dose. The data also highlighted robust efficacy and favorable tolerability, supporting the potential for a convenient monthly dosing regimen. This news follows Pfizer's strategic acquisition of Metsera's obesity assets in April, underscoring the company's aggressive entry into the highly lucrative weight loss market. A drug with this level of efficacy and a potential monthly dosing advantage could be a significant differentiator and a major revenue driver for Pfizer. The company plans to initiate 10 Phase 3 Berobenatide studies in 2026 as part of its broader commitment to over 20 obesity trials.
At the time of this announcement, PFE was trading at $25.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $148.4B. The 52-week trading range was $23.08 to $28.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.